10x Genomics $TXG Shares Purchased by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lifted its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 3,619.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,166,723 shares of the company's stock after acquiring an additional 1,135,356 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.95% of 10x Genomics worth $10,185,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. ARK Investment Management LLC boosted its holdings in shares of 10x Genomics by 7.5% in the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock worth $112,143,000 after buying an additional 901,656 shares during the last quarter. Vanguard Group Inc. lifted its holdings in 10x Genomics by 1.7% during the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock valued at $97,061,000 after purchasing an additional 184,537 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in 10x Genomics by 10.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock valued at $30,394,000 after purchasing an additional 193,588 shares in the last quarter. Voloridge Investment Management LLC lifted its holdings in 10x Genomics by 12.1% during the fourth quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock valued at $22,774,000 after purchasing an additional 171,161 shares in the last quarter. Finally, Two Sigma Investments LP lifted its holdings in 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after purchasing an additional 982,203 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Down 6.7%

Shares of 10x Genomics stock traded down $0.91 during midday trading on Wednesday, hitting $12.59. The company had a trading volume of 2,498,075 shares, compared to its average volume of 2,500,521. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -17.99 and a beta of 2.00. The company has a fifty day simple moving average of $13.22 and a 200 day simple moving average of $10.79. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the company earned ($0.32) EPS. 10x Genomics's quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on TXG shares. UBS Group boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Bank of America upped their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Wall Street Zen raised shares of 10x Genomics from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Zacks Research cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a "hold" rating in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $13.54.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. Corporate insiders own 9.39% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.